Research programme: cervical cancer vaccine - ViciniVax

Drug Profile

Research programme: cervical cancer vaccine - ViciniVax

Alternative Names: SFVeE6,7; Vvax-001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator ViciniVax
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Human papillomavirus E6 protein inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cervical intraepithelial neoplasia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cervical-intraepithelial-neoplasia in Netherlands (IM, Injection)
  • 26 Aug 2013 Research programme: cervical cancer vaccine - ViciniVax is available for licensing as of 26 Aug 2013.
  • 13 Mar 2013 Preclinical trials in Cervical intraepithelial neoplasia in Netherlands (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top